IS4083A - Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja - Google Patents

Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja

Info

Publication number
IS4083A
IS4083A IS4083A IS4083A IS4083A IS 4083 A IS4083 A IS 4083A IS 4083 A IS4083 A IS 4083A IS 4083 A IS4083 A IS 4083A IS 4083 A IS4083 A IS 4083A
Authority
IS
Iceland
Prior art keywords
pharmaceuticals
manufacture
composition
pharmaceutical substances
gel
Prior art date
Application number
IS4083A
Other languages
English (en)
Inventor
Tarantino Ralph
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of IS4083A publication Critical patent/IS4083A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS4083A 1992-10-14 1993-10-13 Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja IS4083A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96075292A 1992-10-14 1992-10-14

Publications (1)

Publication Number Publication Date
IS4083A true IS4083A (is) 1994-04-15

Family

ID=25503572

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4083A IS4083A (is) 1992-10-14 1993-10-13 Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja

Country Status (19)

Country Link
US (1) US5863549A (is)
EP (1) EP0620740B1 (is)
JP (1) JP2613750B2 (is)
CN (1) CN1090509A (is)
AT (1) ATE180976T1 (is)
AU (1) AU672441B2 (is)
CA (1) CA2125784A1 (is)
DE (1) DE69325256T2 (is)
ES (1) ES2133413T3 (is)
IL (1) IL107207A0 (is)
IS (1) IS4083A (is)
LV (1) LV10180A (is)
MX (1) MX9306239A (is)
NZ (1) NZ256413A (is)
RU (1) RU94033520A (is)
SI (1) SI9300468A (is)
UY (1) UY23665A1 (is)
WO (1) WO1994008623A1 (is)
ZA (1) ZA937459B (is)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD358485S (en) 1992-10-05 1995-05-23 Colgate-Palmolive Company Toothbrush handle
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US6264902B1 (en) 1996-06-28 2001-07-24 Johnson & Johnson Medical, Inc. Instrument sterilization container having an improved latching mechanism
US6379631B1 (en) 1996-06-28 2002-04-30 Johnson & Johnson Medical, Inc. Instrument sterilization container formed of a liquid crystal polymer
JP2002519310A (ja) * 1998-06-29 2002-07-02 ファーマシューティカルズ アプリケーションズ アソシエイツ， エルエルシー 疼痛軽減のための方法および経皮組成物
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
AU755443C (en) * 1998-07-20 2006-08-17 Virbac (Australia) Pty Limited Bioimplant formulation
EP1104296B1 (en) 1998-07-20 2012-06-13 Peptech Animal Health Pty Limited Bioimplant formulation
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
US6979459B1 (en) 2000-04-06 2005-12-27 Perricone Nicholas V Treatment of skin damage using polyenylphosphatidycholine
US6191121B1 (en) * 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
US6932963B2 (en) 2000-06-23 2005-08-23 Nicholas V. Perricone Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
US20020106406A1 (en) * 2000-12-08 2002-08-08 Mchugh Anthony J. Crystallizable/non-crystallizable polymer composites
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
KR20040091100A (ko) * 2002-03-04 2004-10-27 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. 운반체 펩타이드를 함유하는 서방형 의약 조성물
EP1485066B1 (fr) 2002-03-12 2016-09-21 Ethypharm Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
KR100906547B1 (ko) 2002-03-12 2009-07-07 에띠빠흠 생활성 물질의 지속적 전달을 위한 겔화 특성을 갖는 조성물
US20040025791A1 (en) * 2002-08-09 2004-02-12 Applied Materials, Inc. Etch chamber with dual frequency biasing sources and a single frequency plasma generating source
FR2868704B1 (fr) * 2004-04-07 2007-09-14 Ethypharm Sa Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires
WO2006002050A1 (en) * 2004-06-15 2006-01-05 Encore Therapeutics, Inc. Phospholipid compositions and methods for their preparation and use
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
MX2007013213A (es) * 2005-04-25 2007-12-12 Amgen Inc Composiciones de liberacion prolongada de peptidos biodegradables que contienen porogenos.
US7695633B2 (en) * 2005-10-18 2010-04-13 Applied Materials, Inc. Independent control of ion density, ion energy distribution and ion dissociation in a plasma reactor
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
PT1787658E (pt) 2005-11-10 2012-06-22 Chemi Spa Formulações de libertação sustentada de análogos de somatostatina inibidores da hormona do crescimento
US8017159B2 (en) * 2005-11-16 2011-09-13 Idexx Laboratories, Inc. Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same
US20070245960A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion density
US20070246161A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Plasma reactor apparatus with a toroidal plasma source and a VHF capacitively coupled plasma source with variable frequency
US20070246163A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Plasma reactor apparatus with independent capacitive and inductive plasma sources
US20070246162A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Plasma reactor apparatus with an inductive plasma source and a VHF capacitively coupled plasma source with variable frequency
US7645357B2 (en) * 2006-04-24 2010-01-12 Applied Materials, Inc. Plasma reactor apparatus with a VHF capacitively coupled plasma source of variable frequency
US7727413B2 (en) * 2006-04-24 2010-06-01 Applied Materials, Inc. Dual plasma source process using a variable frequency capacitively coupled source to control plasma ion density
US20070245958A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Dual plasma source process using a variable frequency capacitively coupled source for controlling ion radial distribution
US7780864B2 (en) * 2006-04-24 2010-08-24 Applied Materials, Inc. Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion radial distribution
US20070245961A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Dual plasma source process using a variable frequency capacitively coupled source for controlling plasma ion dissociation
US20070246443A1 (en) * 2006-04-24 2007-10-25 Applied Materials, Inc. Process using combined capacitively and inductively coupled plasma process for controlling plasma ion dissociation
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
WO2009114959A1 (zh) * 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法
EP2296696B1 (en) 2008-06-05 2014-08-27 ImmunoVaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
MX2011011431A (es) * 2009-05-01 2012-02-23 Ferring Bv Composicion para el tratamiento de cancer de prostata.
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011075623A1 (en) 2009-12-18 2011-06-23 Latitude Pharmaceuticals, Inc. One - phase gel compos ition compri s ing phos pholi pids
CA2809022C (en) 2010-08-20 2017-01-03 Dr. Reddy`S Laboratories, Inc. Phospholipid depot
AU2011317237B2 (en) * 2010-10-22 2015-02-05 Dr. Reddy's Laboratories Sa Use of storage stable viscous phospholipid depot to treat wounds
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
EP2632934B1 (en) 2010-10-27 2016-11-30 Ferring B.V. Process for the manufacture of degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
AU2012267721A1 (en) * 2011-06-09 2013-12-19 Amylin Pharmaceuticals, Llc Gel compositions
ES2855474T3 (es) 2011-10-06 2021-09-23 Immunovaccine Technologies Inc Composiciones de liposomas que comprenden un adyuvante que activa o incrementa la actividad de TLR2 y usos del mismo
EP2846772A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A HYDROPHOBIC ACTIVE SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
FI4512389T1 (fi) 2012-06-01 2025-08-01 Ferring Bv Degareliksilääketuote
KR102227966B1 (ko) * 2019-06-26 2021-03-16 주식회사 엠이티라이프사이언스 비활성 폴리펩타이드 ｔｒｐ의 약제학적 제형

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4252793A (en) * 1979-06-18 1981-02-24 American Lecithin Company Injectable lecithin preparation
US4297353A (en) * 1980-08-04 1981-10-27 Sandoz, Inc. Non-irritating injectable dosage forms
US4578391A (en) * 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
CH668554A5 (de) * 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
GB8603621D0 (en) * 1986-02-14 1986-03-19 Habib N Modifying lipid structure of cell membranes
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CH681427A5 (is) * 1987-07-01 1993-03-31 Zambon Spa
JP2643217B2 (ja) * 1988-01-22 1997-08-20 エーザイ株式会社 脂溶性物質水性液
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5124151A (en) * 1990-08-07 1992-06-23 Mediventures Inc. Drug delivery by injection with thermo-irreversible gels
US5505877A (en) * 1991-10-15 1996-04-09 Krivohlavek; Dennis Making multiple phase emulsion or gel
DE4201527A1 (de) * 1992-01-21 1993-07-22 Knoll Ag Lecithinhaltige loesungen mit levemopamil
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material

Also Published As

Publication number Publication date
ES2133413T3 (es) 1999-09-16
NZ256413A (en) 1996-07-26
MX9306239A (es) 1994-06-30
WO1994008623A1 (en) 1994-04-28
AU5111093A (en) 1994-05-09
IL107207A0 (en) 1994-01-25
JPH06511263A (ja) 1994-12-15
US5863549A (en) 1999-01-26
SI9300468A (en) 1994-06-30
CA2125784A1 (en) 1994-04-28
ATE180976T1 (de) 1999-06-15
EP0620740A1 (en) 1994-10-26
ZA937459B (en) 1994-04-14
UY23665A1 (es) 1994-04-06
DE69325256T2 (de) 1999-12-16
DE69325256D1 (de) 1999-07-15
LV10180A (lv) 1994-10-20
RU94033520A (ru) 1996-11-10
CN1090509A (zh) 1994-08-10
AU672441B2 (en) 1996-10-03
EP0620740B1 (en) 1999-06-09
JP2613750B2 (ja) 1997-05-28

Similar Documents

Publication Publication Date Title
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DE69933208D1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
NO962088L (no) Preparat for in vivo-produksjon av terapeutiske produkter
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DK0656213T3 (da) Kombineret anvendelse af hyaluronsyre og terapeutiske aktivstoffer til forbedring af den terapeutiske effekt
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ATE202923T1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
DK85786D0 (da) Biologisk aktive fragmenter af human antihaemofilisk faktor og fremgangsmaade til fremstilling deraf
DE69615561D1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE400277T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE69426530D1 (de) Pharmazeutische zusammensetzung zur förderung der gewebeheilung und -regenerierung und darreichungssatz
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
ATE458471T1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
DE60007179D1 (de) Pantothensäure-enthaltende arzneimittel zur behandlung von entzündlichen gelenkserkrankungen
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences